X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs NOVARTIS - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA NOVARTIS SANOFI INDIA/
NOVARTIS
 
P/E (TTM) x 34.8 301.0 11.6% View Chart
P/BV x 7.0 25.6 27.3% View Chart
Dividend Yield % 1.3 1.4 90.7%  

Financials

 SANOFI INDIA   NOVARTIS
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
NOVARTIS
Mar-17
SANOFI INDIA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs4,560855 533.3%   
Low Rs4,400666 661.1%   
Sales per share (Unadj.) Rs1,028.5219.0 469.6%  
Earnings per share (Unadj.) Rs129.019.1 675.2%  
Cash flow per share (Unadj.) Rs186.020.3 916.3%  
Dividends per share (Unadj.) Rs68.0010.00 680.0%  
Dividend yield (eoy) %1.51.3 115.4%  
Book value per share (Unadj.) Rs753.6307.0 245.5%  
Shares outstanding (eoy) m23.0329.96 76.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.43.5 125.5%   
Avg P/E ratio x34.739.8 87.3%  
P/CF ratio (eoy) x24.137.5 64.3%  
Price / Book Value ratio x5.92.5 240.0%  
Dividend payout %52.752.4 100.7%   
Avg Mkt Cap Rs m103,17422,779 452.9%   
No. of employees `0003.60.7 537.5%   
Total wages/salary Rs m3,5921,393 257.9%   
Avg. sales/employee Rs Th6,537.79,736.2 67.1%   
Avg. wages/employee Rs Th991.42,066.8 48.0%   
Avg. net profit/employee Rs Th819.8849.0 96.6%   
INCOME DATA
Net Sales Rs m23,6866,562 360.9%  
Other income Rs m708702 100.9%   
Total revenues Rs m24,3947,264 335.8%   
Gross profit Rs m5,281259 2,039.8%  
Depreciation Rs m1,31336 3,657.4%   
Interest Rs m157 208.3%   
Profit before tax Rs m4,661917 508.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691345 490.0%   
Profit after tax Rs m2,970572 519.0%  
Gross profit margin %22.33.9 565.1%  
Effective tax rate %36.337.6 96.4%   
Net profit margin %12.58.7 143.8%  
BALANCE SHEET DATA
Current assets Rs m15,6739,731 161.1%   
Current liabilities Rs m6,6781,830 364.8%   
Net working cap to sales %38.0120.4 31.5%  
Current ratio x2.35.3 44.1%  
Inventory Days Days7649 156.1%  
Debtors Days Days2225 88.7%  
Net fixed assets Rs m8,09857 14,157.3%   
Share capital Rs m230141 163.7%   
"Free" reserves Rs m17,0889,056 188.7%   
Net worth Rs m17,3569,196 188.7%   
Long term debt Rs m00-   
Total assets Rs m25,40011,499 220.9%  
Interest coverage x311.7128.4 242.8%   
Debt to equity ratio x00-  
Sales to assets ratio x0.90.6 163.4%   
Return on assets %11.85.0 233.2%  
Return on equity %17.16.2 275.0%  
Return on capital %26.910.1 268.0%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,145129 5,543.1%   
Fx outflow Rs m6,8461,734 394.8%   
Net fx Rs m299-1,605 -18.6%   
CASH FLOW
From Operations Rs m3,226-380 -850.1%  
From Investments Rs m-1,5554,208 -37.0%  
From Financial Activity Rs m-1,818-3,318 54.8%  
Net Cashflow Rs m-147510 -28.8%  

Share Holding

Indian Promoters % 0.0 0.0 -  
Foreign collaborators % 60.4 75.0 80.5%  
Indian inst/Mut Fund % 14.4 2.0 720.0%  
FIIs % 14.6 1.6 912.5%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.5 48.8%  
Shareholders   15,184 41,647 36.5%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   NATCO PHARMA  PANACEA BIOTECH  CADILA HEALTHCARE  ABBOTT INDIA  PLETHICO PHARMA  

Compare SANOFI INDIA With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades on a Volatile Note; Idea Cellular Plunges 6%(12:30 pm)

After opening the day flat share markets in India are trading on a dull note and are presently trading marginally below the dotted line.

Related Views on News

ABBOTT INDIA at All Time High; BSE HEALTHCARE Index Up 0.5%

Jun 25, 2018 | Updated on Jun 25, 2018

ABBOTT INDIA share price has hit an all time high at Rs 7,550 (up 1.60%). The BSE HEALTHCARE Index is up by 0.49%. Among the top gainers in the BSE HEALTHCARE Index today are ABBOTT INDIA (up 1.60%) and SANOFI INDIA (up 0.37%). The top losers include GSK PHARMA (down 0.04%) and JUBILANT LIFE SCIENCES (down 0.13%).

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Alert: Pharma Stocks Are About to Shoot Up - And a Superb Stock for Trading(Profit Hunter)

Jun 13, 2018

The ailing pharma stocks are bouncing back to health. Read this to find out the best way to profit from them.

Will You Dump Your Client if You're Busy? Inox Wind's Auditor Just Did...(The 5 Minute Wrapup)

Jun 14, 2018

After Inox Wind, you may see more auditors resigning And the reasons can be as funny as they can get.

GST Will Not Solve Problem of High Prices of Petrol and Diesel(Vivek Kaul's Diary)

Jun 13, 2018

Though it will bring transparency in their pricing and that in itself will be a welcome move.

Should You Invest In Mirae Asset Healthcare Fund?(Outside View)

Jun 15, 2018

Mirae Asset Mutual Fund launches NFO - Mirae Asset Helathcare Fund.

This Behaviour is Injurious to Wealth Building(Sector Info)

Jun 13, 2018

Blindly following the herd can be the biggest wealth destroyer.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Jun 25, 2018 03:13 PM

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - STRIDES SHASUN LTD COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS